Methotrexate for Crohn's disease: Experience in a district general hospital

European Journal of Gastroenterology and Hepatology

Volumn 17, Issue 9, 2005, Pages 893-898

  Hayee, B H ^a   Harris, A W ^a  

^a KENT AND SUSSEX HOSPITAL   (United Kingdom)

Author keywords

Crohn's; District general; Methotrexate; Procollagen

Indexed keywords

AZATHIOPRINE; CIPROFLOXACIN; CORTICOSTEROID; MERCAPTOPURINE; MESALAZINE; METHOTREXATE;

ADULT; AGED; CLINICAL ARTICLE; CROHN DISEASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ERYTHEMA NODOSUM; FEMALE; GENERAL HOSPITAL; HEPATITIS; HUMAN; MAINTENANCE DRUG DOSE; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PNEUMONIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; AGED; CROHN DISEASE; DIFFUSION OF INNOVATION; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; FOLIC ACID ANTAGONISTS; GASTROINTESTINAL AGENTS; HOSPITALS, DISTRICT; HOSPITALS, GENERAL; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 23944525347     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200509000-00002     Document Type: Review

References (18)

1. Carter MJ, Lobo AJ, Travis SPL. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53(suppl V):v1-v16.
2. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000; CD000545.
3. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000; CD000067.
4. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease The North American Crohn's Study Group Investigators. N Engl J Med 1995; 332:292-297.
5. Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000; 342:1627-1632.
6. Hanauer SB, Feagan BF, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al., and the ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002; 359:1541-1549.
7. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab (Remicade) is safe, effective and steroid-sparing in Crohn's disease: preliminary results from the ACCENT I trial. Gastroenterology 2001; 120:A21.
8. Teare JP, Sherman D, Greenfield SM, Simpson J, Bray G, Catterall AP, et al. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet 1993; 342:895-898.
9. Mahadevan U, Marion JF, Present DH. Fistula response to methotrexate in Crohn's disease: a case series. Aliment Pharmacol Ther 2003; 18: 1003-1008.
10. Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther 2001; 15:35-44.
11. Goodman TA, Polisson RP. Methotrexate: adverse reactions and major toxicities. Rheum Dis Clin North Am 1994; 20:513-528.
12. Kremer JM, Alarcon GS, Lightfoot RW, Willkens RF, Furst DE, Williams HJ, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring of liver toxicity. Arthritis Rheumatism 1994; 37:316-328.
13. Golden MR, Katz RS, Balk RA, Golden HE. The relationship of pre-existing lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol 1995; 22:1043-1047.
14. Alarcon GS, Kremer JM, Macaluso M, Weinblatt ME, Cannon GW, Palmer WR, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: a multi-centre, case-control study. Ann Intern Med 1997; 127:356-364.
15. Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med 1994; 121:833-841.
16. Te HS, Schiano TD, Kuan SF, Hanauer SB, Conjeevaram HS, Baker AL. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000; 95:3150-3156.
17. Rosenburg WMC, Woelker M, Thiel R, Becka M, Burl A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127:1704-1713.
18. British National Formulary 2005; 49 (section 8.1.3) pp. 414-416. © British Medical Association and Royal Pharmaceutical Association of Great Britain. ISBN 0853695849.